Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives $42.75 Average Price Target from Analysts

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $42.75.

A number of analysts have recently weighed in on KLRA shares. TD Cowen initiated coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 target price on the stock. Wall Street Zen raised shares of Kailera Therapeutics to a “hold” rating in a research note on Saturday, April 25th. Leerink Partners initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating and a $36.00 price target for the company. William Blair initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating for the company. Finally, Jefferies Financial Group initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $48.00 price target for the company.

Kailera Therapeutics Price Performance

Kailera Therapeutics stock opened at $19.55 on Tuesday. Kailera Therapeutics has a twelve month low of $19.11 and a twelve month high of $28.23.

Insider Buying and Selling

In other news, Director Andrew T. Kaplan purchased 8,398,438 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the purchase, the director owned 26,255,581 shares in the company, valued at approximately $420,089,296. This trade represents a 47.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Adam Koppel purchased 1,562,500 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were purchased at an average cost of $16.00 per share, with a total value of $25,000,000.00. Following the completion of the purchase, the director owned 22,583,268 shares in the company, valued at $361,332,288. This trade represents a 7.43% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 10,460,938 shares of company stock valued at $167,375,008.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.